NasdaqGS:MCRB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. More Details


Snowflake Analysis

Limited growth with imperfect balance sheet.

Share Price & News

How has Seres Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MCRB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.8%

MCRB

-3.4%

US Biotechs

-2.4%

US Market


1 Year Return

909.3%

MCRB

35.9%

US Biotechs

18.2%

US Market

Return vs Industry: MCRB exceeded the US Biotechs industry which returned 39.3% over the past year.

Return vs Market: MCRB exceeded the US Market which returned 19.5% over the past year.


Shareholder returns

MCRBIndustryMarket
7 Day-4.8%-3.4%-2.4%
30 Day27.1%0.7%4.2%
90 Day593.6%-4.7%6.3%
1 Year909.3%909.3%38.3%35.9%20.9%18.2%
3 Year214.4%214.4%18.5%12.5%41.2%31.8%
5 Year6.6%6.6%17.2%8.9%84.8%63.9%

Price Volatility Vs. Market

How volatile is Seres Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Seres Therapeutics undervalued compared to its fair value and its price relative to the market?


Share Price vs. Fair Value

Below Fair Value: MCRB ($32.6) is trading above our estimate of fair value ($10.47)

Significantly Below Fair Value: MCRB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MCRB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MCRB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MCRB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MCRB has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Next Steps

Future Growth

How is Seres Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

40.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MCRB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MCRB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MCRB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MCRB's revenue (58.5% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: MCRB's revenue (58.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MCRB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Seres Therapeutics performed over the past 5 years?

-5.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MCRB is currently unprofitable.

Growing Profit Margin: MCRB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MCRB is unprofitable, and losses have increased over the past 5 years at a rate of 5.7% per year.

Accelerating Growth: Unable to compare MCRB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MCRB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: MCRB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Seres Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: MCRB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MCRB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MCRB has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MCRB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MCRB has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: MCRB is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Seres Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MCRB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MCRB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MCRB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MCRB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MCRB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Eric Shaff (44 yo)

1.75yrs

Tenure

US$2,032,548

Compensation

Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer of Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off ...


CEO Compensation Analysis

Compensation vs Market: Eric's total compensation ($USD2.03M) is below average for companies of similar size in the US market ($USD5.61M).

Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Eric Shaff
President1.75yrsUS$2.03mno data
Matthew Henn
Executive VP & Chief Scientific Officer1.67yrsUS$859.45k0%
$ 0
Thomas DesRosier
Chief Legal Officer4.42yrsUS$977.34k0%
$ 0
Marcus Chapman
Senior VP of Finance and Principal Financial & Accounting Officer2.75yrsno data0.0096%
$ 280.3k
John Aunins
CTO and Executive VP of Bioprocess & Manufacturing7.83yrsno data0.12%
$ 3.4m
Carlo Tanzi
VP of Investor Relations & Corporate Communications4.92yrsno datano data
Jeff York
Vice President of Human Resources3.42yrsno datano data
James Weston
Senior Vice President of Regulatory Affairs3.42yrsno datano data
Lisa von Moltke
Executive VP & Chief Medical Officer0.58yrno datano data
Teresa Young
Executive VP and Chief Commercial & Strategy Officer0.33yrno datano data
Caroline Holda
Assistant General Counselno datano datano data

3.1yrs

Average Tenure

54yo

Average Age

Experienced Management: MCRB's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Eric Shaff
President1.75yrsUS$2.03mno data
Charles Cooney
Member of Scientific Advisory Boardno datano datano data
Willard Dere
Independent Director3.25yrsUS$75.65k0%
$ 0
Dennis Ausiello
Independent Director5.5yrsUS$69.23k0%
$ 0
Kurt Graves
Independent Director4.92yrsUS$78.15k0%
$ 0
Richard Kender
Independent Director6yrsUS$88.15k0%
$ 0
Mark Wilcox
Member of Scientific Advisory Board5.75yrsno datano data
Grégory Behar
Independent Director5.83yrsUS$71.65k0%
$ 0
Andrew Goodman
Member of Scientific Advisory Boardno datano datano data
Curtis Huttenhower
Member of Scientific Advisory Boardno datano datano data
Peter Turnbaugh
Member of Scientific Advisory Boardno datano datano data
Stephen Berenson
Independent Chairman0.83yrUS$62.76kno data

5.2yrs

Average Tenure

61.5yo

Average Age

Experienced Board: MCRB's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.7%.


Top Shareholders

Company Information

Seres Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Seres Therapeutics, Inc.
  • Ticker: MCRB
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.911b
  • Shares outstanding: 89.29m
  • Website: https://www.serestherapeutics.com

Number of Employees


Location

  • Seres Therapeutics, Inc.
  • 200 Sidney Street
  • 4th Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MCRBNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJun 2015
1S9DB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2015

Biography

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The com ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 00:31
End of Day Share Price2020/10/19 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.